Literature DB >> 15961793

Strontium ranelate for the treatment of osteoporosis.

Ignac Fogelman, Glen M Blake.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15961793      PMCID： PMC558360          DOI： 10.1136/bmj.330.7505.1400

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

Authors:  J Y Reginster; E Seeman; M C De Vernejoul; S Adami; J Compston; C Phenekos; J P Devogelaer; M Diaz Curiel; A Sawicki; S Goemaere; O H Sorensen; D Felsenberg; P J Meunier
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

2.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors:  B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

3.  Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration.

Authors:  G Boivin; P Deloffre; B Perrat; G Panczer; M Boudeulle; Y Mauras; P Allain; Y Tsouderos; P J Meunier
Journal:  J Bone Miner Res       Date:  1996-09       Impact factor: 6.741

4.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

5.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

6.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

7.  Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.

Authors:  Ann Cranney; Gordon Guyatt; Lauren Griffith; George Wells; Peter Tugwell; Clifford Rosen
Journal:  Endocr Rev       Date:  2002-08       Impact factor: 19.871

8.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Authors:  S R Cummings; D M Black; D E Thompson; W B Applegate; E Barrett-Connor; T A Musliner; L Palermo; R Prineas; S M Rubin; J C Scott; T Vogt; R Wallace; A J Yates; A Z LaCroix
Journal:  JAMA       Date:  1998 Dec 23-30       Impact factor: 56.272

9.  The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.

Authors:  Pierre J Meunier; Christian Roux; Ego Seeman; Sergio Ortolani; Janusz E Badurski; Tim D Spector; Jorge Cannata; Adam Balogh; Ernst-Martin Lemmel; Stig Pors-Nielsen; René Rizzoli; Harry K Genant; Jean-Yves Reginster
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

10.  Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry.

Authors:  S P Nielsen; D Slosman; O H Sørensen; B Basse-Cathalinat; P De Cassin; C R Roux; P J Meunier
Journal:  J Clin Densitom       Date:  1999       Impact factor: 2.963
View more
  6 in total

1.  Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis.

Authors:  H Y Lee; D Lie; K S Lim; T Thirumoorthy; S M Pang
Journal:  Osteoporos Int       Date:  2008-07-04       Impact factor: 4.507

2.  Alopecia associated with strontium ranelate use in a 62-year-old woman.

Authors:  Y-Y Lee; C-H Yang; C-H Chen; J-S Hwang
Journal:  Osteoporos Int       Date:  2012-04-12       Impact factor: 4.507

3.  Increased risk of strontium ranelate-related SJS/TEN is associated with HLA.

Authors:  H Y Lee; M X Shen; Y L Lim; Y K Tay; M M F Chan; S M Pang; Z W Xiao; S B Ang; E C Ren
Journal:  Osteoporos Int       Date:  2016-03-22       Impact factor: 4.507

Review 4.  Treatment of primary osteoporosis in men.

Authors:  Andrea Giusti; Gerolamo Bianchi
Journal:  Clin Interv Aging       Date:  2014-12-30       Impact factor: 4.458

Review 5.  Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy.

Authors:  Glen M Blake; Ignac Fogelman
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

6.  Effects of Strontium-Doped β-Tricalcium Scaffold on Longitudinal Nuclear Factor-Kappa Beta and Vascular Endothelial Growth Factor Receptor-2 Promoter Activities during Healing in a Murine Critical-Size Bone Defect Model.

Authors:  Mersedeh Tohidnezhad; Yusuke Kubo; Philipp Lichte; Tobias Heigl; Diana Roch; Nazanin Barahmand Pour; Christian Bergmann; Tolga Taha Sönmez; Jennifer Vanessa Phi Hock; Athanassios Fragoulis; Felix Gremse; Stefanie Rosenhain; Alexander Slowik; Michaela Bienert; Nisreen Kweider; Christoph Jan Wruck; Holger Jahr; Frank Hildebrand; Hans Christoph Pape; Sabine Neuß; Horst Fischer; Thomas Pufe
Journal:  Int J Mol Sci       Date:  2020-05-01       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.